Pacific Biosciences of California
PACB
2.72
+0.02
+0.74%
Pacific Biosciences of California
US · PACB
#3373 by market cap
2.72
+0.02
+0.74%
Live - 5344 symbols - heartbeat 517s ago
· 2026-10-08 09:10
Pre-market
2.65
-2.57%
After-hours
2.70
-0.74%
Overnight
2.72
0.00%
- Market cap
- 845.46M
- P/E (TTM)i
- -6.48
- P/Bi
- -25.42
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on PACB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -5.84, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.89% YoY
Margins
- Gross margin
- 28.61%
- Operating margin
- -348.46%
- Net margin
- -341.47%
Key ratios & quality
- Enterprise valuei
- 1.21B
- Altman Z-Scorei
- -5.84
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.63M | 90.89M | 78.89M | 130.51M | 128.30M | 200.52M | 154.01M | 160.01M |
| Gross profit | 25.10M | 34.58M | 32.57M | 58.86M | 49.04M | 52.78M | 37.28M | 45.78M |
| Selling & admin expenses | 63.49M | 75.49M | 72.80M | 124.12M | 160.85M | 169.82M | 175.02M | 141.49M |
| Research & development | 62.59M | 59.63M | 64.15M | 112.90M | 193.00M | 187.17M | 134.92M | 97.31M |
| Operating profit | -100.99M | -100.55M | -104.39M | -178.16M | -304.82M | -310.37M | -290.66M | -557.56M |
| Pretax profit | -102.56M | -84.13M | 29.40M | -274.87M | -314.25M | -318.16M | -309.54M | -546.06M |
| Tax | -- | 0 | 0 | -93.65M | 0 | -11.42M | 316.00K | 318.00K |
| Net profit | -102.56M | -84.13M | 29.40M | -181.22M | -314.25M | -306.74M | -309.85M | -546.38M |
| Basic EPS | -1 | -1 | 0 | -1 | -1 | -1 | -1 | -2 |
| Diluted EPS | -0.76 | -0.55 | 0.17 | -0.89 | -1.40 | -1.21 | -1.59 | -1.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 37.15M | 39.77M | 38.44M | 44.65M | 37.18M | 39.01M |
| Gross profit | -1.37M | 14.68M | 15.90M | 16.57M | 12.84M | 12.64M |
| Selling & admin expenses | 40.17M | 36.18M | 31.10M | 34.05M | 31.15M | 33.39M |
| Research & development | 29.05M | 22.53M | 22.85M | 22.88M | 19.61M | 23.02M |
| Operating profit | -432.63M | -44.85M | -38.88M | -41.20M | -54.15M | -44.61M |
| Pretax profit | -426.38M | -41.90M | -37.62M | -40.17M | -8.09M | -44.68M |
| Tax | -302.00K | 35.00K | 383.00K | 202.00K | 184.00K | 58.00K |
| Net profit | -426.08M | -41.93M | -38.00M | -40.37M | -8.28M | -44.74M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -1.44 | -0.14 | -0.13 | -0.13 | -0.03 | -0.14 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 131.66M | 81.05M | 355.59M | 1.10B | 852.07M | 742.05M | 495.68M | 375.05M |
| Cash & ST investments | 102.35M | 49.10M | 318.81M | 1.04B | 772.32M | 631.42M | 389.93M | 279.51M |
| Inventory | 17.88M | 13.31M | 14.23M | 24.60M | 50.38M | 56.68M | 58.76M | 49.29M |
| Total assets | 170.28M | 147.99M | 413.98M | 2.01B | 1.77B | 1.75B | 1.26B | 784.08M |
| Total current liabilities | 26.88M | 49.15M | 38.50M | 71.71M | 263.34M | 95.03M | 66.30M | 72.83M |
| Short-term debt | -- | 19.71M | 4.33M | 9.32M | 10.73M | 10.08M | 10.03M | 448.00K |
| Long-term debt | 14.66M | -- | -- | 896.07M | 896.68M | 892.24M | 647.49M | 645.38M |
| Total liabilities | 56,214,000.00 | 93,068,000.00 | 78,489,000.00 | 1,215,983,000.00 | 1,204,182,000.00 | 1,044,709,000.00 | 753,853,000.00 | 778,734,000.00 |
| Total equity | 114.06M | 54.92M | 335.49M | 790.99M | 562.90M | 701.30M | 506.59M | 5.35M |
| Retained earnings | -982.11M | -1.07B | -1.04B | -1.22B | -1.53B | -1.84B | -2.15B | -2.70B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 444.92M | 413.40M | 394.24M | 375.05M | 369.52M | 338.64M |
| Cash & ST investments | 343.11M | 314.74M | 298.65M | 279.51M | 275.96M | 236.87M |
| Inventory | 54.01M | 53.84M | 53.15M | 49.29M | 51.02M | 61.08M |
| Total assets | 860.79M | 825.47M | 803.16M | 784.08M | 782.37M | 751.85M |
| Total current liabilities | 66.60M | 59.75M | 63.21M | 72.83M | 65.36M | 68.81M |
| Short-term debt | 2.42M | 703.00K | 621.00K | 448.00K | 277.00K | 1.37M |
| Long-term debt | 646.21M | 646.44M | 645.16M | 645.38M | 644.11M | 644.33M |
| Total liabilities | 769,151,000.00 | 763,981,000.00 | 767,068,000.00 | 778,734,000.00 | 779,999,000.00 | 785,063,000.00 |
| Total equity | 91.64M | 61.49M | 36.09M | 5.35M | 2.37M | -33.21M |
| Retained earnings | -2.58B | -2.62B | -2.65B | -2.70B | -2.70B | -2.75B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -66.43M | -78.31M | 19.50M | -111.18M | -263.21M | -259.17M | -206.06M | -111.21M |
| Depreciation & amortization | 7.22M | 9.95M | 9.30M | 11.59M | 17.32M | 26.53M | 53.35M | 386.41M |
| Free cash flow | -68.28M | -81.15M | 18.46M | -117.11M | -280.14M | -268.02M | -212.25M | -118.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 97.53M | 0 | 187.48M | 294.85M | 0 | 189.20M | 0 | 0 |
| Ending cash balance | 23.64M | 33.93M | 85.95M | 460.73M | 325.09M | 182.63M | 57.59M | 65.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -44.06M | -29.38M | -18.71M | -19.07M | -44.69M | -35.58M |
| Depreciation & amortization | 372.78M | 4.58M | 4.40M | 4.65M | 4.07M | 4.52M |
| Free cash flow | -50.45M | -29.93M | -18.62M | -19.93M | -52.73M | -39.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 58.51M | 56.64M | 58.30M | 65.26M | 56.27M | 62.61M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -102.48 | -99.58 | 15.06 | -32.18 | -46.42 | -48.53 | -51.30 | -213.45 |
| ROA %i | -65.25 | -52.87 | 10.46 | -14.97 | -16.65 | -17.46 | -20.61 | -53.45 |
| ROIC %i | -87.67 | -61.52 | 11.98 | -16.30 | -18.40 | -18.62 | -21.27 | -57.33 |
| 5-year avg ROE %i | -92.08 | -90.68 | -77.80 | -65.43 | -53.12 | -42.33 | -32.67 | -78.38 |
| EBIT margin %i | -127.36 | -89.69 | 37.61 | -201.01 | -233.48 | -151.51 | -192.27 | -336.93 |
| FCF / sales %i | -- | -- | 23.40 | -- | -- | -- | -- | -- |
| Current ratioi | 4.90 | 1.65 | 9.24 | 15.36 | 3.24 | 7.81 | 7.48 | 5.15 |
| Quick ratioi | 4.13 | 1.31 | 8.72 | 14.90 | 3.00 | 7.03 | 6.30 | 4.32 |
| Debt / assetsi | 8.61 | 41.67 | 10.15 | 47.60 | 53.67 | 53.49 | 53.35 | 89.59 |
| LT debt / equityi | 12.85 | 76.41 | 11.23 | 119.60 | 166.59 | 131.73 | 130.76 | 13,123.46 |
| Interest coveragei | -41.33 | -31.22 | 111.12 | -20.94 | -20.39 | -21.18 | -22.08 | -77.52 |
| Revenue CAGR (3Y) %i | -5.37 | 0.07 | -5.49 | 18.40 | 12.18 | 36.47 | 5.67 | 7.64 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -177.61 | -189.96 | -205.90 | -213.45 | -273.55 | -929.32 |
| ROA %i | -51.98 | -45.09 | -44.70 | -53.45 | -15.65 | -16.66 |
| ROIC %i | -54.71 | -47.62 | -47.14 | -57.33 | -16.63 | -17.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -424.11 | -330.88 | -320.36 | -336.93 | -75.50 | -77.37 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.68 | 6.92 | 6.24 | 5.15 | 5.65 | 4.92 |
| Quick ratioi | 5.63 | 5.81 | 5.21 | 4.32 | 4.67 | 3.89 |
| Debt / assetsi | 81.22 | 84.71 | 87.17 | 89.59 | 89.91 | 93.92 |
| LT debt / equityi | 760.27 | 1,136.00 | 1,938.10 | 13,123.46 | 29,717.29 | -- |
| Interest coveragei | -55.83 | -52.87 | -62.13 | -77.52 | -17.37 | -16.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Consumable revenue is the largest reported line at 51.56% of revenue, across 3 reported segments.
- Instrument revenue follows at 32.91%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Consumable revenue51.56%
Instrument revenue32.91%
Service and other revenue15.53%
Quote time 2026-10-08 09:10:31 · For reference only, not investment advice and not tailored to your situation.